The FDA has granted Priority Review to nipocalimab for warm autoimmune hemolytic anemia treatment based on positive findings from the ENERGY trial.

In late April 2026, Johnson & Johnson reported multiple milestones, including FDA Priority Review for IMAAVY ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; ...

Phase 2b LUMINA 2 study data support rilzabrutinib's FDA Breakthrough Therapy designation for the treatment of warm autoimmune hemolytic anemia. The Food and Drug Administration (FDA) has granted ...

Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) for IMAAVY® ...

Autoimmune hemolytic anemia (AIHA) and paroxysmal nocturnal hemoglobinuria (PNH) are distinct blood disorders with different underlying causes and treatment approaches. Each is rare and potentially ...

Cold antibody hemolytic anemia is a rare autoimmune disorder characterized by the premature destruction of red blood cells by autoantibodies at temperatures of approximately 0 to 10 degrees Celsius. Q ...

Additional population-based studies of autoimmune hemolytic anemia and its management are needed to reduce mortality in this patient population. Autoimmune hemolytic anemia (AIHA) is typically a ...

The FDA has approved Pyrukynd (mitapivat) for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency. The Food and Drug Administration (FDA) has approved Pyrukynd ® (mitapivat) ...

Mihir Raval, MD, MPH, comments on the difference between cold agglutinin disease and other autoimmune hemolytic anemias. Neil Minkoff, MD: Now, you had mentioned that there are other autoimmune ...

Case 1. A 17-year-old boy was admitted to Walter Reed General Hospital for repair of an ostium-primum defect of the interatrial septum with an associated cleft mitral valve and mitral insufficiency.